Jul 15, 2026 07:30AM
Jul 15, 2026 07:30AM
Jun 1, 2026 08:05AM
Jun 1, 2026 08:05AM
May 14, 2026 07:15AM
May 11, 2026 08:05AM
May 5, 2026 07:10AM Cellectar reports 12-month data for cancer drug in rare blood disorder
May 5, 2026 07:10AM
May 5, 2026 07:03AM
May 5, 2026 07:00AM
Apr 21, 2026 10:01AM
Apr 21, 2026 10:00AM
Apr 14, 2026 08:35AM
Apr 14, 2026 08:35AM Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Mar 4, 2026 07:15AM
Feb 25, 2026 08:05AM
Feb 17, 2026 08:05AM
Jan 9, 2026 08:05AM
Nov 13, 2025 07:20AM
Nov 6, 2025 08:05AM
Oct 27, 2025 08:33AM Cellectar receives rare pediatric disease designation for brain cancer drug
Oct 27, 2025 08:30AM
Oct 14, 2025 08:30AM
Oct 14, 2025 08:30AM
Oct 7, 2025 08:31AM
Oct 7, 2025 08:30AM
Oct 6, 2025 07:01AM
Oct 6, 2025 07:00AM Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi
Sep 30, 2025 08:30AM
Sep 24, 2025 08:30AM
Sep 9, 2025 08:05AM
Sep 5, 2025 08:45AM
Sep 3, 2025 08:05AM
Aug 27, 2025 08:05AM
Aug 14, 2025 07:19AM Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Aug 7, 2025 08:05AM
Jun 26, 2025 08:05AM
Jun 26, 2025 08:05AM
Jun 24, 2025 08:30AM
Jun 18, 2025 04:30PM
Jun 18, 2025 04:30PM
Jun 11, 2025 08:05AM Cellectar Biosciences (CLRB) Provides Update on CLOVER-2 Phase 1 Trial
Jun 11, 2025 08:05AM
Jun 5, 2025 09:00AM
Jun 5, 2025 09:00AM
Jun 4, 2025 01:04PM
Jun 4, 2025 08:05AM
Jun 4, 2025 08:05AM
May 13, 2025 07:05AM Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 7, 2025 08:05AM

326,538 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All